Two cannabis-based medicines approved for use on the NHS for the first time

The journey so far

Back in November 2018, the law changed to allow specialist doctors to legally issue prescriptions for cannabis-based medicines if they feel that their patients could benefit from this treatment. Though, lack of clinical trials and concrete evidence as to the long term benefits and safety of the treatment, has meant that most doctors have been unwilling to write prescriptions.

In a number of instances, families have taken to seeking treatment abroad at great expense. The decision to make these fully licensed for routine use by the NHS is therefore a positive step, though many have questioned whether it is far enough.

What has been the reaction?

While 9,000 people in the UK are affected by Lennox Gastaut and Dravet syndrome, there are a number of other forms of epilepsy that won’t benefit from this new treatment.

Due to a lack of evidence, NICE also ruled out prescribing drugs containing THC, which many have found to be an effective treatment for chronic pain, a common symptom of MS.

The Centre for Medical Cannabis (CMC) welcomed the new NICE guidelines, though urges the government to accelerate patient access and clinical learning via the NHS. A shocking new poll conducted for CMC, revealed that 1.4 million British adults were sourcing ‘street cannabis’ to treat the symptoms of chronic conditions. Further information and statistics can be found here.

Memery Crystal

CEO and Senior Corporate Partner Nick Davis commented: “Whilst being delighted that certain patients are now able to access cannabis-based medicines on the NHS, there is a long way to go. I look forward to further reviews by the NHS to ensure that all patients can access the medicine they need. I would urge the government to look at the Danish model as an example that is working well for all patients”.

At Memery Crystal, we will continue to fight for patient access to the medicinal cannabis they need through advising the sector on business set up, capital markets, mergers and acquisitions, private fundraising, licensing, and commercial contracts.

As legislation and attitudes change, we are proud to be at the centre of it.